Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$24.77
-2.7%
$30.15
$12.75
$44.32
$4.36B1.031.75 million shs525,878 shs
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$92.58
+0.3%
$90.36
$43.89
$101.00
$5.67B0.63759,055 shs158,813 shs
FibroGen, Inc. stock logo
FGEN
FibroGen
$1.00
-6.7%
$1.87
$0.33
$19.47
$98.56M0.72.45 million shs1.09 million shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
$64.41
$4.12B0.772.76 million shsN/A
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$239.24
+2.0%
$232.48
$204.44
$261.54
$11.26B0.52434,168 shs229,345 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
+1.56%+0.87%-13.93%-29.75%+67.39%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
+1.85%+7.20%+6.03%+12.71%+92.07%
FibroGen, Inc. stock logo
FGEN
FibroGen
-6.14%-17.69%-58.53%+10.28%-93.66%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%+35.44%
United Therapeutics Co. stock logo
UTHR
United Therapeutics
+0.18%+1.16%-1.44%+7.16%+2.71%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
4.5619 of 5 stars
4.41.00.03.92.74.20.6
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.7289 of 5 stars
2.33.00.00.01.70.80.6
FibroGen, Inc. stock logo
FGEN
FibroGen
4.5038 of 5 stars
2.94.00.04.73.83.30.6
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.2 of 5 stars
1.10.00.04.70.60.00.6
United Therapeutics Co. stock logo
UTHR
United Therapeutics
4.4136 of 5 stars
3.40.00.04.63.13.31.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.80
Moderate Buy$47.8293.05% Upside
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.50
Moderate Buy$85.43-7.72% Downside
FibroGen, Inc. stock logo
FGEN
FibroGen
1.75
Reduce$17.001,603.58% Upside
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
2.21
Hold$60.002.21% Upside
United Therapeutics Co. stock logo
UTHR
United Therapeutics
2.89
Moderate Buy$294.2522.99% Upside

Current Analyst Ratings

Latest FGEN, BBIO, MRTX, UTHR, and BPMC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$114.00
3/21/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$45.00
3/20/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$35.00 ➝ $45.00
3/19/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$60.00 ➝ $70.00
3/7/2024
United Therapeutics Co. stock logo
UTHR
United Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$309.00 ➝ $325.00
3/5/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $53.00
3/4/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
2/27/2024
FibroGen, Inc. stock logo
FGEN
FibroGen
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
2/26/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$97.00
2/23/2024
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$42.00 ➝ $46.00
2/22/2024
United Therapeutics Co. stock logo
UTHR
United Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$308.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$9.30M468.31N/AN/A($7.72) per share-3.21
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$249.38M22.72N/AN/A$2.15 per share43.06
FibroGen, Inc. stock logo
FGEN
FibroGen
$147.75M0.67N/AN/A($1.87) per share-0.53
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$12.44M331.01N/AN/A$17.31 per share3.39
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$2.33B4.84$22.57 per share10.60$127.35 per share1.88

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$643.20M-$3.94N/AN/AN/A-6,913.92%N/A-110.39%5/2/2024 (Estimated)
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$506.98M-$8.36N/AN/AN/A-203.30%-191.56%-45.25%5/2/2024 (Confirmed)
FibroGen, Inc. stock logo
FGEN
FibroGen
-$284.23M-$2.93N/AN/AN/A-192.37%N/A-51.00%5/13/2024 (Estimated)
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/A
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$984.80M$19.8412.069.54N/A42.31%17.72%14.47%5/1/2024 (Estimated)

Latest FGEN, BBIO, MRTX, UTHR, and BPMC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/2/2024N/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$1.65-$1.66-$0.01N/AN/AN/A  
2/26/2024Q4 2023
FibroGen, Inc. stock logo
FGEN
FibroGen
-$0.42-$0.57-$0.15-$0.57$40.00 million$27.14 million
2/22/2024Q4 2023
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.87-$0.96-$0.09-$0.96$4.78 million$1.74 million
2/21/202412/31/2023
United Therapeutics Co. stock logo
UTHR
United Therapeutics
$4.28$4.36+$0.08$4.36$575.01 million$614.70 million      
2/15/202412/31/2023
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$2.04-$1.82+$0.22-$1.82$67.34 million$71.96 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
FibroGen, Inc. stock logo
FGEN
FibroGen
N/AN/AN/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/A
United Therapeutics Co. stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
3.32
3.32
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
1.60
3.76
3.66
FibroGen, Inc. stock logo
FGEN
FibroGen
N/A
1.52
1.33
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
7.54
7.40
United Therapeutics Co. stock logo
UTHR
United Therapeutics
0.05
4.41
4.28

Ownership

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
FibroGen, Inc. stock logo
FGEN
FibroGen
72.71%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
United Therapeutics Co. stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
28.52%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
3.88%
FibroGen, Inc. stock logo
FGEN
FibroGen
2.39%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
3.26%
United Therapeutics Co. stock logo
UTHR
United Therapeutics
12.50%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
550175.83 million125.69 millionOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
65561.20 million58.83 millionOptionable
FibroGen, Inc. stock logo
FGEN
FibroGen
48698.77 million96.41 millionOptionable
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
58770.15 million67.86 millionOptionable
United Therapeutics Co. stock logo
UTHR
United Therapeutics
1,16847.06 million41.18 millionOptionable

FGEN, BBIO, MRTX, UTHR, and BPMC Headlines

SourceHeadline
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
zacks.com - April 24 at 1:16 PM
United Therapeutics Announces World’s First Successful Xenothymokidney TransplantUnited Therapeutics Announces World’s First Successful Xenothymokidney Transplant
finance.yahoo.com - April 24 at 12:57 PM
United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?United Therapeutics (UTHR) Earnings Expected to Grow: Should You Buy?
zacks.com - April 24 at 11:07 AM
United Therapeutics Announces Worlds First Successful Xenothymokidney TransplantUnited Therapeutics Announces World's First Successful Xenothymokidney Transplant
businesswire.com - April 24 at 9:00 AM
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
businesswire.com - April 24 at 7:00 AM
United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares of StockUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares of Stock
americanbankingnews.com - April 24 at 4:56 AM
Martine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockMartine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock
insidertrades.com - April 24 at 4:47 AM
United Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from AnalystsUnited Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from Analysts
americanbankingnews.com - April 24 at 2:48 AM
United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 SharesUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares
marketbeat.com - April 23 at 6:40 PM
Duality Advisers LP Acquires 5,622 Shares of United Therapeutics Co. (NASDAQ:UTHR)Duality Advisers LP Acquires 5,622 Shares of United Therapeutics Co. (NASDAQ:UTHR)
marketbeat.com - April 23 at 7:52 AM
Zurcher Kantonalbank Zurich Cantonalbank Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)Zurcher Kantonalbank Zurich Cantonalbank Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)
marketbeat.com - April 22 at 5:48 AM
United Therapeutics CEO Martine Rothblatt sells $1.7m in stockUnited Therapeutics CEO Martine Rothblatt sells $1.7m in stock
investing.com - April 21 at 3:02 PM
United Therapeutics Corporation (UTHR)United Therapeutics Corporation (UTHR)
finance.yahoo.com - April 21 at 3:02 PM
United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Vontobel Holding Ltd.United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Vontobel Holding Ltd.
marketbeat.com - April 21 at 5:24 AM
International Assets Investment Management LLC Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)International Assets Investment Management LLC Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR)
marketbeat.com - April 20 at 4:42 AM
Leerink Partnrs Brokers Cut Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)Leerink Partnrs Brokers Cut Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)
americanbankingnews.com - April 20 at 2:42 AM
Leerink Partnrs Comments on United Therapeutics Co.s FY2024 Earnings (NASDAQ:UTHR)Leerink Partnrs Comments on United Therapeutics Co.'s FY2024 Earnings (NASDAQ:UTHR)
marketbeat.com - April 19 at 8:50 AM
United Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform RatingUnited Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform Rating
markets.businessinsider.com - April 18 at 8:23 AM
United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $835,380.00 in StockUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $835,380.00 in Stock
insidertrades.com - April 18 at 6:16 AM
United Therapeutics Co. (NASDAQ:UTHR) to Post Q1 2024 Earnings of $5.93 Per Share, Leerink Partnrs ForecastsUnited Therapeutics Co. (NASDAQ:UTHR) to Post Q1 2024 Earnings of $5.93 Per Share, Leerink Partnrs Forecasts
americanbankingnews.com - April 18 at 5:48 AM
Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of StockInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of Stock
marketbeat.com - April 17 at 6:38 PM
United Therapeutics CEO Martine Rothblatt sells shares worth over $1.7 millionUnited Therapeutics CEO Martine Rothblatt sells shares worth over $1.7 million
investing.com - April 16 at 11:57 PM
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International ConferenceUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
finance.yahoo.com - April 16 at 8:55 AM
Louisiana State Employees Retirement System Makes New $2.90 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)Louisiana State Employees Retirement System Makes New $2.90 Million Investment in United Therapeutics Co. (NASDAQ:UTHR)
marketbeat.com - April 16 at 6:51 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

BridgeBio Pharma logo

BridgeBio Pharma

NASDAQ:BBIO
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
Blueprint Medicines logo

Blueprint Medicines

NASDAQ:BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
FibroGen logo

FibroGen

NASDAQ:FGEN
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Mirati Therapeutics logo

Mirati Therapeutics

NASDAQ:MRTX
Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
United Therapeutics logo

United Therapeutics

NASDAQ:UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.